GlaxoSmithKline PLC (GSK) witnessed a remarkable surge of 6.97% in intraday trading on Wednesday, driven by the company's better-than-expected fourth-quarter earnings, an optimistic long-term outlook, and a share buyback announcement.
The British pharmaceutical giant reported core earnings per share of 23.2 pence for the fourth quarter of 2024, surpassing analysts' estimates of 19 pence. The company's sales for the quarter reached £8.12 billion, exceeding the consensus forecast of £7.83 billion, fueled by strong performance in its specialty medicines portfolio, particularly in oncology and HIV treatments.
Furthermore, GSK lifted its 2031 sales forecast to more than £40 billion, up from the previous target of £38 billion. This increased outlook reflects the company's promising pipeline developments and expected new medicines launches between 2025 and 2031, including oncology treatments. The company also announced a £2 billion share buyback program to be implemented over the next 18 months.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。